Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Kenneth Blum, Research Professor at Western University Health Sciences and Ariel University
What This Means Clinically For patients who have tried GLP-1 medications and experienced significant side effects, or who are not candidates for appetite-suppressing approaches, AOD 9604 represents a mechanistically different option
For insulin resistance, studies have explored dosages ranging from 200 mg to 3,000 mg daily
Do not expect overnight fairness
Summary: How retatrutide is dosed is based solely on Phase 2 clinical trial protocols, starting at 2 mg once weekly subcutaneously and escalating gradually to a maximum of 12 mg, as the drug remains unlicensed in the UK with no MHRA-approved dosing schedule
